AUM Biosciences attended the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, on 1st to 4th December 2018

San Diego, 1 - 4 December 2018

AUM Biosciences will be attended the 60th American Society of Hematology (ASH) Annual Meeting and Exposition on 1st to 4th December 2018 in sunny San Diego. Touted as “world’s most comprehensive Hematology event of the year”, we were excited to participate in the invaluable educational exchanges and vibrant discussions on the hottest topics in Hematology. A perfect opportunity for collaboration, if you attended as well, we’d be keen to connect. Drop us a note!

For more information, please click here.

For any additional queries, please contact

About AUM Biosciences

AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company committed to developing affordable cancer therapies. Dedicated to unlocking the value in innovation, AUM harnesses the power of precision medicine and digital health to support patients, physicians and partners. AUM focuses on earlystage development of innovative treatment of cancers prevalent in Asia with the potential to address global markets.

AUM develops potent and highly selective therapeutics in oncology, with an aim to change the drug development paradigm by implementing a holistic approach to developing drugs. AUM Biosciences is led by a highly-experienced management team with over 75 years of high-quality oncology drug development experience combined.

Headquartered in Singapore, AUM is strategically positioned to work, partner and collaborate with leading research institutes, clinicians and pharmaceutical companies globally. AUM is the recipient of Frost & Sullivan’s 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year. For more information, please visit